Human neural progenitor cells (hNPCs) have been proposed as a potential source of cells for ex vivo gene therapy. In this pilot study, three 5-year-old female cynomolgus monkeys received a single intracarotid infusion of MPTP, followed 1 week later by MRI-guided stereotaxic intrastriatal and intranigral injections of male hNPCs transgenic for GDNF. Immunosupression with oral cyclosporine (30-40 mg/kg) began 48 h before hNPC transplants and continued throughout the study. We monitored the animals using a clinical rating scale (CRS). Three months postsurgery, we euthanized the animals by transcardiac perfusion, then retrieved and processed their brains for morphological analysis. Our findings include the following. 1) hNPCs survived and produced GDNF in all animals 3 months postsurgery. 2) hNPCs remained in the areas of injection as observed by GDNF immunostaining and in situ hybridization for the human Y chromosome. 3) A "halo" of GDNF expression was observed diffusing from the center of the graft out into the surrounding area. 4) We observed increased TH-and VMAT2-positive fibers in areas of GDNF delivery in two of the three animals. The two animals with TH-and VMAT2-positive fibers also showed reductions in their CRS scores. 5) Some GFAP-positive perivascular cuffing was found in transplanted areas. 6) General blood chemistry and necropsies did not reveal any abnormalities. Therefore, we conclude that hNPCs releasing GDNF may be a possible alternative for intracerebral trophic factor delivery in Parkinson's disease. 383 384 EMBORG ET AL.
INTRODUCTION
pumps (16, 24) . Alternatives to delivery using pumps are in vivo gene therapy where virus expressing the GDNF transcript directly infects host brain cells (3, 4) or ex vivo Chronic localized intracerebral delivery is an essential requirement for therapeutic molecules aiming to gene therapy where cells in the culture dish are infected with the same virus and then transplanted (27) . In vivo treat neurodegenerative disorders. Glial-derived neurotrophic factor (GDNF) is a potent trophic factor for gene delivery of GDNF, in which a viral vector encoding for GDNF was introduced into the nigrostriatal sys-dopamine neurons and a candidate trophic therapy for Parkinson's disease (17, 25, 30) . Although controversy tem, stimulated dopaminergic function in aged monkeys and prevented the structural and functional conse-surrounds the clinical use of GDNF (32) , its neuroprotective and regenerative effects in animal models of PD quences of nigrostriatal degeneration in young MPTPor 6-OHDA-treated monkeys (14, 22) . Although the re-have been independently corroborated by several laboratories (5, 14, 15, 19, 22, 23, (39) (40) (41) . Like other trophic fac-sults are promising, and there are currently a number of clinical trials under way using direct gene therapy tors, GDNF requires intracerebral site-specific delivery to be effective and decrease the risk of side effects (23). approaches in PD (39) , the possibility to use in vivo gene therapy to deliver a potent trophic factor through-Targeted delivery of GDNF protein in patients can be accomplished by continuous infusion via cannulae and out extensive areas of the basal ganglia presents some problems and risks that have to be considered. For ex-nosuppression paradigms in the primate, (iii) long-term expression of GDNF, and (iv) regulation of gene expres-ample, it is unclear what effect the viral infection of endogenous host cells and subsequent forced expression sion to prevent excessive accumulation over time that may have unwanted side effects. The experiments pre-of a foreign protein will have on their function, and how this may affect the patient. One way to overcome this is sented here target the first three challenges and show that under the conditions used there is only limited mi-to use exogenous cells to deliver GDNF rather than infect the patient's own cells. The production of GDNF gration from the transplant site, that the immune suppression is sufficient but not perfect, and that GDNF can be monitored and the best batches of cells producing predictable amount of GDNF can be selected. Moreover, release can be maintained for up to 3 months, leading to a very significant increase in tyrosine hydroxylase (TH) the chances of introducing live virus into the patient is essentially zero. activity confined to the region of the transplant. Thus, these cells represent a unique way to deliver GDNF to Kishima and colleagues (20) pursued the concept of ex vivo gene therapy using encapsulated GDNF-produc-very localized regions of the primate brain that in turn can regulate dopaminergic function. ing C2C12 cells in chronic MPTP-treated baboons. The investigators found transitory improvement of parkinso-MATERIALS AND METHODS nian signs, significant protection of striatal terminals Subjects located close to the capsule placement, and significant increase in nigral dopaminergic bodies. The partial im-Three female cynomolgus monkeys were housed at provement observed in this experiment was probably rethe Wisconsin National Primate Research Center, Unilated to the location of the capsules in the intraventricuversity of Wisconsin-Madison, in single quarters with a lar system which limited the distribution of GDNF to 12-h light/dark cycle. The animals received food and the areas close to the ventricular system. Although mawater ad libitum. We performed the study in accordance croencapsulation technique ensures that the cells are with federal guidelines for proper animal care and with contained and can be retrieved in case of complications, approval from the campus animal care committee. it limits the distribution of the product to the immediate hNPC Growth and Infection in Culture vicinity to the capsule and, depending on the cell line, it may require periodic exchange of the capsules to ensure Human cortical neural progenitor cells were isolated the presence of healthy living cells producing GDNF (4) .
from primary human fetal cortex between 10 and 15 Direct transplantation of genetically modified cells is weeks of gestation, according to protocols approved by an attractive alternative-in particular using lines dethe NIH, the local ethics committee at the University of rived from stem cells. In addition to the advantages as-Wisconsin-Madison, and the University of Washington sociated with ex vivo gene therapy, the cells may be Birth Defects Laboratory. Following dissociation in able to integrate with host tissue, migrate to areas where 0.1% trypsin, 200,000 cells/ml were seeded in T75 they are needed, and thus have a better distribution of flasks containing DMEM/Ham's F12 (Gibco-BRL). The GDNF. Human neural progenitor cells (hNPCs) can be cells were supplemented with penicillin/streptomycin genetically modified to release glycosylated GDNF and (1%; Gibco-BRL), N2 (1%; Gibco-BRL), epidermal survive transplantation into rodent models of Parkingrowth factor (EGF, 20 ng/ml; Sigma) with heparin (5 son's disease (2) . These cells have significant functional µg/ml; Sigma), and fibroblast growth factor-2 (FGF-2, effects in this model when releasing GDNF or another 20 ng/ml; R&D). Neurosphere colonies rapidly formed powerful growth factor, like insulin growth factor-1 and expanded via an automated tissue chopper (38). At (IGF-1) (8) . These cells could also survive and release second passage, cells were maintained in DMEM/F12/ GDNF 3 months following transplantation into an aged PSA media supplemented with N2 and EGF. After 10 monkey brain (2) . Importantly, no tumors were found in passages, leukemia inhibitory factor (LIF, 20ng/ml; any animal.
Chemicon) was added to the media. The cultures could These findings support the concept that hNPC can be then be stably grown for additional passages (42) . genetically modified and can be an option for delivering Lentiviral Infection growth factors to specific targets within the central nervous system for diseases such as Parkinson's disease.
As described in detail previously (6) , the mouse phosphoglycerate kinase 1 (PGK) promoter drives GDNF ex-Yet certain challenges have to be overcome before hNPCs delivery of therapeutic molecules can be as-pression. The posttranslational cis-acting regulatory element of the woodchuck hepatitis virus (WHV) is sessed in the clinic (37) . In particular, the following studies will need to be performed in primates: (i) con-included and has been shown to significantly enhance transgene expression. The lentiviral particles were sus-trolling the migration and proliferation of hNPC within the parkinsonian primate brain, (ii) evaluation of immu-pended in 1% fetal bovine serum albumin in phosphate-buffered saline (PBS). The cells were accutase disso-one injection in the substantia nigra (5 µl). The rate of infusion was 1 µl/min. The syringe remained in place ciated at 15 million cells at passage 6 and plated in 24-well plates at 300,000 cells/well. The cells were for an additional 3 min after injection. infected with lentivirus at 100 ng/million cells, then col-Immunosuppression lected into flasks after 72 h and expanded as neurospheres until transplantation.
The immunosuppressant cyclosporine was administered orally once per day (30-40 mg/kg), starting 48 h Preparation of Cells for Transplantation before stem cell surgery and continuing throughout the study. Monkeys were handled for drug administration GDNF-overexpressing neurospheres were collected at passage 16 and 22. They were disassociated with ac-with a pole-and-collar handling system (12). Two months before surgery, the animals received training by cutase and treated with a trypsin inhibitor and DNAse. They were collected and resuspended to a density of positive reinforcement so that they could be removed from their cages and walk to a restrainer. After several 150,000 cells/µl in transplantation media (Leibowitz, L-15; Sigma), 2% B27 supplement, in 0.6% glucose in training sessions, they received oral administration of 1 ml/kg of saline via a lubricated endogastric tube (16 sterile PBS. The cells remained on ice for the duration of the transplantation procedure. frame). Periodic blood sampling monitored drug levels, general chemistry, and hematological parameters.
GDNF ELISA and Immunocytochemistry
Necropsy and Preparation of Tissue Cells remaining after transplantation were plated at a density of 40,000 cells/well on cover slips in a 24-well Three months after the stem cell infusions, the monkeys were euthanized with pentobarbital (25 mg/kg, IV) plate. After 1 day in culture, half the cells were fixed with 4% paraformaldehyde (PFA) and stained for and perfused transcardially with heparinized normal saline, followed by 4% paraformaldehyde. The brain was GDNF. The cells were washed with PBS, blocked with 5% normal donkey serum, incubated in primary GDNF removed from the calvaria and slabbed in the coronal plane with a calibrated Lucite brain slice apparatus. antibody (goat anti-human GDNF, 1:100; R&D Systems), then incubated in cy3 conjugated secondary anti-Slabs were immersed in 4% paraformaldehyde for 48 h of fixation and then cryoprotected by immersion in a body (donkey anti-goat, 1:1000; Jackson Immunolabs). Hoescht nuclear dye was added and then cover slips re-graded (10-40%) sucrose/0.1 M PBS (pH 7.2) solution.
The tissue slabs were cut frozen (40 µm) on a sliding moved and mounted on microscope slides.
To quantify GDNF release, the other half of the knife microtome. All sections were stored in a cryoprotectant solution before processing. plated cells was cultured for an additional 2 weeks. At the end of this culture period, the media was changed Immunohistochemistry and collected and the cells were counted 24 h later. The media was analyzed using GDNF ELISA (R&D Sys-Sections through midbrain and striatum were used for immunohistochemical staining of TH, vesicular mono tems) and calculated at nanogram total of GDNF/h/million cells.
amino transport 2 (VMAT2), GDNF, CD68 (macrophages), and glial fibrilar acidic protein (GFAP), accord-MPTP Treatment ing to previously published protocol (11,23,28,34). Under sterile surgical conditions, each monkey re-Immunofluorescence ceived a single infusion of 3 mg of MPTP-HCl in 20 ml of saline (rate: 1.33 ml/min), according to previously All procedures occurred at room temperature unless otherwise noted. Brain tissue sections underwent wash-published protocols (10,12,13). We evaluated the animals weekly using a clinical rating scale (9,13) to assess ing for 1 h with PBS, incubation for 15 min in 3% H 2 O 2 in PBS, and washing with PBS/0.05% Triton-TX. Sec-the effect of MPTP lesioning and general behavior.
tions incubated in 3% normal donkey serum (NDS) in Intracerebral Stem Cell Injections PBS/0.05% Triton and 2% bovine serum albumin (BSA) for 1 h and then remained in primary antibody solution One week after MPTP administration, the three monkeys received six MRI-guided stereotaxic intracerebral overnight at 4°C. This solution contained rabbit antinestin (1:10,000; Chemicon) and goat anti-biotinylated injections of GDNF-releasing stem cells, following previously described protocols (22). All injections occurred GDNF (1:50; R&D Systems) in PBS/0.01% Triton, 1% NDS, and 1% BSA. Sections were then washed in PBS/ in the same side (right) of the MPTP ICA infusion. The animals received two injections in the caudate (volume: 0.01% Triton and incubated in a secondary antibody solution for 1 h. The secondary solution contained donkey rostral 10 µl and caudal 5 µl), three injections in the putamen (rostral 10 µl, medial 10 µl, caudal 5 µl), and anti-rabbit cy3 (1:1000; Jackson ImmunoResearch) and streptavidin conjugated alexafluor 488 (1:500; Molecu-arm contralateral to the lesion side (scores: Cy0077 = 10.5; Cy0095 = 10.5; Cy0105 = 13). lar Probes) in PBS/0.01% Triton, 1% NDS, and 1% BSA. The sections were then mounted onto glass micro-Immunosuppression scope slides with cover slips using Immunotech mounting media.
Immunosuppression therapy with cyclosporine A (CsA) began 48 h before transplantation. As previously Y Probe In Situ Hybridization described (31) , the animals presented individual varia-Sections were placed in 0.2 M HCl at room temperations in how they metabolized cyclosporine. One monture for 20 min. Rinsing occurred twice in distilled water key had consistently lower blood levels of cyclosporine and once in 2× SSC. Slides were placed in preheated (Cy0077, 62 ng/ml to below the detectable level of 25 pretreatment solution (sodium isothiocyanate, Vysis, ng/ml) compared to the other monkeys (Cy0095, 239 to Downers Grove, IL) at 80°C for 30 min, followed by 39 ng/ml; Cy0105, 219 to 42 ng/ml), even after the anithree rinses at room temperature with 2× SSC. Sections mal's dose was increased from 30 to 40 mg/kg PO. Genwere digested in protease III (proteinase K, 3.9 µg/ml) eral hematology and chemistry panel at the time of death and in proteinase buffer III (Vysis) at 37°C for 10 min, did not show abnormalities. followed by three rises in 2× SSC. Sections were dena-Identification of hNPCs by In Situ Hybridization Using tured for 5 min at 73°C in formamide/SSC solution (49 the Y-Chromosome Probe ml formamide/7 ml of 20× SSC/14 ml of water), then dehydrated through a graded series of ethanols. A CEP Three months after hNPC transplantation the animals XY DNA FISH probe (Vysis) was applied to the secwere perfused and the brains removed and sectioned. tions; they were sealed under glass cover slips, and then Identification of hNPCs in the monkey brain was comincubated overnight at 42°C. The next day, cover slips plicated by the cross-reactivity of "human-specific" antiwere removed in 2× SSC, slides were rinsed for 2 min bodies such as human nuclear antigen (2) with monkey in 2× SSC/0.1% Nonidet P-40 at 73°C, allowed to air antigens. In order to address this issue, male hNPCs dry, and mounted in Vectorshield mounting medium (carrying a Y-chromosome) were transplanted into fewith DAPI (Vector Lab. Inc., Burllingame, CA). We male hosts, allowing unequivocal identification of the viewed the sections using a fluorescence microscope donor cells by applying in situ hybridization to the Y (Zeiss Axiovision Microscope, Carl Zeiss Inc., Thornprobe. In the region of the transplant, nearly every nuwood, NY).
cleus showed a small, punctuated Y probe signal indicating that the hNPCs had survived within the transplant RESULTS region in all three animals (Fig. 2) . However, there were Production of GDNF-Secreting Progenitor Cells no Y probe-positive nuclei in the regions next to any of the transplants. This suggests that there was little or no GDNF production by hNPC was assessed in vitro becell migration into host monkey brain tissue. fore transplantation and after transplantation in the remaining nongrafted cells that were subsequently plated
In Vivo Production of GDNF and Phenotypic and allowed to differentiate. After 2 weeks half of the Differentiation of hNPCs wells we fixed and processed for GDNF immunohisto-GDNF immunostaining revealed evidence of GDNFchemistry and 80.5% showed strong positive staining.
secreting cells in all three monkeys 3 months after trans-The other half was left to mature for an additional 2 plantation (Fig. 3) . The GDNF expression was localized weeks in culture. Twenty-four hours following a media within the target areas (Figs. 4A and B and 5A) , correchange, GDNF release was analyzed using ELISA sponding to the areas identified as the transplant with (mean of six independent wells). The analysis revealed the Y probe hybridization. We observed a dark core of a strong production of GDNF, ranging between 900 and GDNF activity with a halo of reduced staining surround-1600 pg/h/10 6 cells. GDNF release in control lines not ing this region and extending into the host striatum or infected with GDNF was below assay detection limits substantia nigra (Fig. 5B, C) . We saw very few individ-( Fig. 1) .
ual cells in the periphery of the GDNF expression, sug-MPTP Effects gesting that most of the GDNF was extracellular, as seen previously in rodent studies (2, 21) . Before MPTP administration, the three animals presented normal active behaviors according to their ages, as
In order to establish the phenotype of the transplanted hNPCs, we performed immunofluorescence costaining previously described (11). Seventy-two hours after intracarotid MPTP administration, a typical hemiparkinsonian for human-specific nestin (a progenitor cell marker) and GDNF (Fig. 3) . We found multiple nestin-positive cells syndrome was observed that included bradykinesia, gait disturbances, and gross motor skill impairments in the that had processes reaching out into the primate stria- Figure 1 . GDNF hNPCs expressed measurable levels of GDNF in vitro. Immediately following transplantation, GDNF hNPCs were plated in six wells and cultured for 2 weeks. ELISA measurements of conditioned media showed that GDNF expression levels ranged from 900 pg/h/million cells to 1.5 ng/hr/million cells. Data from the six wells are graphed individually. Immunocytochemistry for GDNF in plated hNPCs shows clear GDNF expression (in red) in GDNF transduced cells, whereas untransduced cells do not express GDNF (negative control). hNPC nuclei are labeled in blue. tum. Thus, although there was little migration of cells on the Y probe marker ( Figs. 3 and 6 ). These probably represented host reactive astrocytes, which presumably from the transplant, they did appear to put out processes away from the core, which resulted in a halo of GDNF were responding to the transplant and may have either been a sign of mild inflammation and rejection or a re-expression ( Fig. 3) . A number of cells within the transplant also expressed the astrocyte marker GFAP (Fig. sponse to the direct trauma of injecting cells. 6). However, this protein is also found in the hNPCs Effect of hNPC GDNF on the Host Dopamine System while they are dividing and, therefore, is not a reliable and Behavior indication of glial differentiation (43). Interestingly, there were many GFAP-positive cells around the trans-
We have previously shown that widespread direct gene delivery of GDNF using viral vectors was able to plant in regions where there were no human cells based fibers correlated exactly with GDNF expression (Figs.  5A, B and 6A ). We observed small intrinsic TH-and VMAT2-positive cells in the right and left striatum but found higher numbers in the areas of GDNF expression. In one animal (Cy0105), we observed scarce TH-positive ( Fig. 4D ) and VMAT2-positive (Fig. 5F ) fibers within the transplant region, even though we saw strong GDNF expression and good cell survival (Fig. 4B) . Interestingly, this animal presented the most severe lesion of the dopamine system as evidenced by the highest score of the three monkeys in the clinical rating and an almost complete lack of TH ( Fig. 4D) and VMAT2 (fig.  4F ) staining in both the lateral and ventral regions of the striatum and the nucleus accumbens.
The two animals showing the most robust TH and VMAT2 expression in response to GDNF also showed progressive declines in the overall clinical rating scores (improvement of their parkinsonian signs), starting 6 weeks posttransplantation (final score: Cy0077, 2; Cy0095, 4.5). However, the animal that did not show increases in TH and VMAT2 expression with the more complete lesion maintained a constant higher score (final score: Cy0105, 8). While this is of interest, it is difficult to draw firm correlations between behavior and anatomy given the small number of animals and the lack of a nontransplant control group.
Immunological Response to hNPCs
Some GFAP-positive perivascular cuffing was found in target regions (Fig. 6 ). Assessment of host reaction with CD68 revealed minimal macrophage recruitment following the needle tract in Cy0077 and Cy0095 (data not shown). CD68 immunoreactivity was more pronounced in Cy0105, in particular in caudal target areas where GDNF was not present (Fig. 7) .
CONCLUSION AND DISCUSSION
GDNF has long been considered a possible treatment for Parkinson's disease. Recent clinical studies using of delivery should be considered (32) . In this report, we the core of nestin-positive cells (red). Scale bar: 25 µm.
have established that hNPCs genetically modified to overexpress GDNF were able to survive and produce GDNF for 3 months in a nonhuman primate brain undergoing MPTP-induced neurodegeneration. The GDNF-protect/restore dopamine function after MPTP toxicity in the nonhuman primate brain (22). We next assessed releasing cells were able to partially restore the host dopaminergic nigrostriatal system when transplanted 1 whether the GDNF released by hNPCs was also able to induce changes in host dopaminergic markers. In two of week after neurotoxin exposure. There was some apparent increase in functional recovery in the animals, which the three animals, TH (Figs. 4B and 5D) and VMAT2 (Figs. 4E and 5G), immunostaining revealed distinct showed an upregulation of TH activity and no obvious negative side effects from the transplant procedure. patches of high fiber expression within surrounding areas of very low or no-fiber expression induced by the Unilateral intracarotid MPTP infusion to nonhuman primates induces a syndrome that closely resembles hu-MPTP. These patches of TH and VMAT2 expression in . GDNF released by GDNF hNPCs increased TH and VMAT2 expression in the host striatum. The pattern of GDNF expression corresponded to the areas of higher TH and VMAT2 immunoreactivity (arrows). Monkey Cy0105 (B, C, D) had decreased DA markers expression compared to Cy0077 (A, C, D) or Cy0095, although strong GDNF expression was found in all monkeys. The dark spot marked with an asterisk in (A) corresponds to a hNPC expressing GDNF just above the striatum in the corpus callosum following the needle tract. As expected, this white matter area did not present TH and VMAT2 expression. Cd, caudate; Pu, putamen; Acb, nucleus accumbens. Scale bar: 1.2 mm. man hemiparkinsonism and is stable over time (13). The induced functional and anatomical consequences (22). Following a similar paradigm, we treated three monkeys time course of a nigrostriatal lesion after a single intracarotid injection of MPTP starts as a loss of striatal DA with a single intracarotid injection of MPTP, evaluated the MPTP-induced deficits, and 1 week later performed that it is noticeable 48 h postexposure as a PD syndrome (13,22). If the hemiparkinsonian signs are moderate to MRI-guided injections of hNPCs overexpressing GDNF. We observed increased TH and VMAT2 immunoreac-severe (scoring 10 or more points using CRS), the syndrome remains stable for many years (13). Eberling and tivity in the areas of GDNF expression in two of the three monkeys. This finding differed from the extensive colleagues (7) documented that in the first few weeks postlesion there is a unilateral loss of striatal dopaminer-expression of GDNF and TH terminal protection found after in vivo gene therapy (22) and poses some interest-gic function (observed as FMT uptake) that does not affect the substantia nigra and explains the motor defi-ing alternatives. If MPTP exposure induces downregulation of the dopaminergic phenotype, early intervention cits. It is not clear if the decline of FMT uptake is due to downregulation of the DA phenotype or terminal de-with GDNF may locally reverse this deleterious effect in passing fibers. If MPTP induces destruction of dopa-struction. By 3 months, morphological examination reveals extensive loss of both TH-immunoreactive striatal minergic terminals, TH-positive fibers could be the product of specific regrowth of terminals due to protec-terminals and nigral neurons. This protracted process provides a window of opportunity for neuroprotective tion of the dopaminergic neurons in the substantia nigra.
Or it could also be associated to sprouting of neighbor-treatment. Intrastriatal and intranigral injections of lenti-GDNF 1 week post-MPTP were able to prevent MPTP-ing terminals. Further studies prelabeling with antero- grade neuronal markers may allow the identification of while in monkeys, MPTP dosing was done by intracarotid administration. We have recently shown that in ro-the origin of these fibers.
Interestingly, the two monkeys that showed increased dents intraparenchimal administration of neurotoxins facilitates both the migration and survival of the hNPC TH immunoreactivity in the areas of GDNF expression also showed TH-positive fibers with a ventro-dorsal gra-GDNF, which only migrate and survive at the graft site in intact animals (1) . However, in the stroke monkey dient towards the graft site. The actual grafts presented a "halo" of GDNF following an outward gradient. Hence, model (28) , in which striatal tissue damage also occurred, hNPC migration was limited and the grafts GDNF spread maybe more extensively than observed with immunohistochemistry because the low levels looked similar to those seen in our MPTP model. These results suggest that specific neural signals or, more sim-spreading into the striatum may not be detected using this method. GDNF dispersion through the surrounding ply, anatomical barriers related to species differences (rodent vs. primate vs. human cells) may also lead to area can be an important issue for the success of the therapy. In that regard, the conflicting results between reduced cell migration. For example, the primate striatum does not have multiple white matter tracts of the the success of two phase I clinical trials (16, 33) and the failure of a phase II trial (24) , all of them using GDNF internal capsula, which provide a preferred substrate for hNPC to migrate along. Clearly more work is needed to intraputaminal infusions, suggests that differences in infusion methods may have caused the discordant results resolve this issue. However, although reduced migration can be considered a shortcoming of the method with re-(32). Salvatore and colleagues (29) recently described that the infusion method and single point cannula system gard to wide distribution of the drug, it can also be interpreted as an advantage as it increases the drug's safety used in the failed trial produced limited diffusion of GDNF, which remained mostly around the single open-through lack of aberrant migration to other brain structures. This specificity of GDNF release within the pri-ing in the catheter tip. Another possibility for the observed TH and VMAT2 increased immunoreactivity is mate brain may be manipulated in future studies through increasing the number of injection sites and cells trans-that hNPCs are releasing trophic molecules, in addition to GDNF, and these maybe also inducing neuroprotec-planted and altering their exact locations. Three months after transplant many hNPCs had not matured into either tion.
One of the monkeys had GDNF-expressing cells but neurons or astrocytes, but instead continued to express nestin. This was similar to our previous results in vari-did not present an increase in TH nigrostriatal expression. Although intracarotid MPTP infusions are more ous models where we transplanted hNPCs at later passages into either the striatum or spinal cord following predictable than other methods of intoxication, there is still some variability among individuals. Although the injury (2, 21, 26, 27, 35) . Perhaps at later time points the cells would downregulate nestin and upregulate GFAP, three monkeys received similar doses of MPTP, the nonresponsive monkey presented the most severe PD syn-as we have shown previously in rodents (36). We found host GFAP-positive reactive astrocytes and drome immediately after MPTP, scoring 13 points in the CRS scale (compared to 10.5 and 11). This animal also CD68-positive reactive macrophages in and around the grafts. However, reactive astrocytes and macrophages had the most complete apparent lesion of the DA system that included the nucleus accumbens, although this is were absent in the intact brain hemispheres of the three monkeys. These findings suggest that the hNPC GDNF difficult to establish as the other animals in the group may have responded to the GDNF-secreting cells. For induced a mild immune response in the nonhuman primate brain. Optimizing the immune suppression regime GDNF therapy to be efficacious it may be necessary for the nigrostriatal dysfunction to be mild to moderate in may be required to reduce this inflammatory effect of the xenografts. This is of special concern as there was a order to elicit a positive outcome. Interestingly, this monkey also had a slightly increased immunogenic re-disassociation between cyclosporine levels and immune reaction in the three animals. The use in future projects sponse to the transplant. Thus, immune rejection effects may have led to the lack of TH activity within the trans-of allografts, HLA matching with hosts, is considered an ideal solution to diminish host immune reaction. plant.
Compared to rodent studies, where the cells are able In conclusion, we have shown that GDNF can be delivered to discrete regions of the parkinsonian primate to migrate across entire structures to reach lesioned areas (2, 18, 25) , in nonhuman primates, neural progenitor brain using human neural progenitor cells. There was an increase in TH-positive fibers within and around the cell migration seems to be more limited (28) . This difference in migration patterns may not be related to the transplant, suggesting that either the dopamine neuronal projections had been protected, or enzyme activity within species but rather to the method of toxin administration in the animals. In rodents, quinolinic acid (26) and 6- the fibers upregulated in response to GDNF. While cell migration was limited, it is not possible to predict what OHDA (2) was introduced directly into the rat striatum,
